» Articles » PMID: 20854460

Screening of Platelets for Bacterial Contamination at the Welsh Blood Service

Overview
Journal Transfus Med
Specialty Hematology
Date 2010 Sep 22
PMID 20854460
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: This report details the results of the implementation of a bacterial screening system at the Welsh Blood Service and provides an estimate of the levels of bacterial contamination at the time of sampling.

Materials And Methods: Apheresis (Caridian BCT) and buffy coat-derived pooled platelet components were sampled on day 1 for bacterial contamination and the sample was monitored throughout the lifespan of the platelet component. Unused platelet components were re-tested to determine the effectiveness of the screening. Results from the BacT/ALERT are uploaded to the in-house Blood Establishment Computer System (BECS) every 12 min. Positive alerts are automatically sent to staff, facilitating a timely intervention.

Results: Between February 2003 and March 2010 the screening system tested 54 828 platelets and detected 257 (1 in 213) initial positives of which 35 (1 in 1567, 0·06%) were confirmed [95% confidence interval (CI), 0·04-0·08%]. Additionally, screening of 6438 unused platelet components detected another 6 (1 in 1073, 0·09%) confirmed positives not detected during initial testing (95% CI, 0·02-0·16%). Analysis of the data suggests that on day 1 the number of bacteria in such platelet component packs was between 5 and 62 cfus total. Day 1 culture has a sensitivity of 40%.

Conclusions: The bacterial screening system has removed a significant number, but not all bacterially contaminated platelet components from the supply. The sample volume is an important factor in sensitivity due to the low number of bacteria in a platelet component pack on day 1. An effective notification and recall system is a critical part of the bacterial screening system.

Citing Articles

Transfusion-associated adverse events and implementation of blood safety measures - findings from the 2017 National Blood Collection and Utilization Survey.

Savinkina A, Haass K, Sapiano M, Henry R, Berger J, Basavaraju S Transfusion. 2020; 60 Suppl 2:S10-S16.

PMID: 32134123 PMC: 7908682. DOI: 10.1111/trf.15654.


Microbiological Screening of Platelet Concentrates in Europe.

Prax M, Bekeredjian-Ding I, Krut O Transfus Med Hemother. 2019; 46(2):76-86.

PMID: 31191193 PMC: 6514488. DOI: 10.1159/000499349.


Bacterial contamination of platelets for transfusion: strategies for prevention.

Levy J, Neal M, Herman J Crit Care. 2018; 22(1):271.

PMID: 30367640 PMC: 6204059. DOI: 10.1186/s13054-018-2212-9.


Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model.

Prioli K, Karp J, Lyons N, Chrebtow V, Herman J, Pizzi L Appl Health Econ Health Policy. 2018; 16(6):889-899.

PMID: 30062464 PMC: 6244623. DOI: 10.1007/s40258-018-0409-3.


Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland.

Jutzi M, Taleghani B, Rueesch M, Amsler L, Buser A Transfus Med Hemother. 2018; 45(3):151-156.

PMID: 29928168 PMC: 6006633. DOI: 10.1159/000489900.